PDHA1 (Pyruvate Dehydrogenase E1 Subunit Alpha 1)

Additionally, the aberrant overexpression of PDHA1 in AnoR prostate cancer cells upregulates PPARA and AIFM2 expression through nuclear translocation, collectively suppressing ferroptosis and promoting metastasis. These findings reveal a novel role for PDHA1 in mediating ferroptosis resistance during ECM detachment and provide a potential therapeutic target for prostate cancer treatment.

While ATP5A1 shows promise in tissue, plasma-based screening benefits from combining multiple markers, including pri-miR-526b. Further research is needed to refine plasma biomarker panels for effective early detection of breast cancer.

P2, N=15, Recruiting, Assistance Publique - Hôpitaux de Paris | Trial completion date: Dec 2026 --> Apr 2027 | Initiation date: May 2025 --> Oct 2025 | Trial primary completion date: Nov 2025 --> Mar 2026 | Not yet recruiting --> Recruiting

Molecular docking highlighted Monomethyl lithospermate as a key active component. Overall, SLC influences oxidative phosphorylation via the PDK1/PDHA1 and SIRT1/PGC-1α/NRF1/TFAM signaling pathways and downregulates the HER2 pathway, thereby ultimately inhibiting HER2-positive breast cancer progression.

PDHA1, OGG1, and OPA1 were identified as potential prognostic markers for pediatric AML, providing valuable insights for the development of targeted therapeutic strategies. However, further validation in larger and more diverse clinical cohorts is still required to confirm its clinical applicability.

These findings provide concrete molecular targets for antiangiogenic therapy and establish clinically actionable biomarkers for glioma patient stratification in the 3PM framework. The online version contains supplementary material available at 10.1007/s13167-025-00428-1.

In vitro experiments, the combination of elesclomol (a copper ion carrier) and bortezomib (Bortezomib) demonstrated a synergistic anti-myeloma effect through excessive intracellular reactive oxygen species generation. This study provides valuable insights into the role of CRGs in MM, potentially aiding in prognosis prediction and the development of effective, personalized therapeutic strategies.

GLS and PDHA1 have been proposed as potential prognostic markers for immunotherapy. Targeting cuproptosis has the potential to convert immunologically cold to hot tumours, thereby advancing precision immunotherapy.

Moreover, it is demonstrated that an artificial R5P signal, generated by ribose-5-sulfate (R5S), sensitizes cancer cells to apoptosis by initiating the cell cycle in the absence of sufficient anabolite supply. These suggest that cancer signatures, including the Warburg effect and angiogenesis, are intrinsically driven by CDH1.

It is well-established that pyruvate dehydrogenase kinase (PDK)-mediated phosphorylation of PDH leads to its inactivation and that dichloroacetic acid (DCA), a PDK inhibitor, has been investigated in preclinical and early clinical studies as a potential therapeutic agent for lung cancer. This study aims to elucidate how PLK1-associated activity drives the metabolic reprogramming from OXPHOS to glycolysis during cellular transformation, thereby contributing to lung carcinogenesis. Our results provide support for a clinical trial to evaluate the efficacy of Onvansertib plus DCA in treating lung cancer.

P=N/A, N=150, Recruiting, University of Pittsburgh | Trial completion date: Aug 2025 --> Sep 2026 | Trial primary completion date: Aug 2025 --> Sep 2026